XOMA Inc.

About XOMA Inc.

XOMA develops biopharmaceuticals that target cancer, immunological disorders and infectious diseases.

LEAD PRODUCT --RAPTIVA -- control of chronic moderate-to-severe plaque psoriasis --APPROVED

PRODUCT PIPELINE

Neuprex - infectious and inflammatory conditions, congenital heart abnormalities

XMP.629 -- Acne

MLN2222 - Coronary artery bypass graft (CABG) surgery patients.

More on XOMA

Home page

Key Statistics for XOMA

Basic Chart for XOMA

Analyst Opinion

Analysts Estimates